NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
47 hedge funds and large institutions have $9.59M invested in NeuBase Therapeutics, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 22 closing their positions.
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
29% less funds holding
Funds holding: 66 → 47 (-19)
37% less capital invested
Capital invested by funds: $15.3M → $9.59M (-$5.69M)
86% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 22
95% less call options, than puts
Call options by funds: $50K | Put options by funds: $1.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.08M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$422K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$316K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$117K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$4.46M |
| 2 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$1.34M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.01M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$481K |
| 5 |
Millennium Management
New York
|
-$236K |
NBSE Hedge Fund Activity: Q3 2015 in Review
47 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2015, worth a combined $9.59M — down 37% from $15.3M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of NBSE and 3 opened new positions — a net loss of 19 holders — while 15 trimmed existing stakes and 14 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $1.08M. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.46M sold.
- 47 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2015, down from 66 in Q2 2015.
- Funds reported $9.59M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2015, down 37% quarter-over-quarter.
- 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2015 and 22 closed out, a net change of -19 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2015 was BlackRock Institutional Trust, an estimated $1.08M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2015 was Broadfin Capital, an estimated $4.46M sold.
Based on aggregated 13F filings for Q3 2015.